Abstract
The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.
| Original language | English (US) |
|---|---|
| Article number | 642 |
| Journal | Frontiers in Pharmacology |
| Volume | 9 |
| Issue number | JUN |
| DOIs | |
| State | Published - Jun 26 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- Activation
- Autoimmune diseases
- Biological agents
- Dendritic cells
- Immunological synapse
- T cell
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. / Tai, Yu; Wang, Qingtong; Korner, Heinrich; Zhang, Lingling; Wei, Wei.
In: Frontiers in Pharmacology, Vol. 9, No. JUN, 642, 26.06.2018.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases
AU - Tai, Yu
AU - Wang, Qingtong
AU - Korner, Heinrich
AU - Zhang, Lingling
AU - Wei, Wei
PY - 2018/6/26
Y1 - 2018/6/26
N2 - The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.
AB - The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.
KW - Activation
KW - Autoimmune diseases
KW - Biological agents
KW - Dendritic cells
KW - Immunological synapse
KW - T cell
UR - http://www.scopus.com/inward/record.url?scp=85049065128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049065128&partnerID=8YFLogxK
U2 - 10.3389/fphar.2018.00642
DO - 10.3389/fphar.2018.00642
M3 - Review article
AN - SCOPUS:85049065128
VL - 9
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
IS - JUN
M1 - 642
ER -